camizestrant

News

ASCO26: After negative adcomm, AZ builds case for oral SERD

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

FDA delays verdict on AZ breast cancer drug

After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.

News

FDA's ODAC delivers one loss, one win for AstraZeneca

The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.

News

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for cla...

The results of the SERENA-2 trial of AstraZeneca’s oral selective estrogen receptor degrader (SERD) camizestrant, reported at the SABCS congress this week, could restore confidence in the m

ASCO26: After negative adcomm, AZ builds case for oral SERD

FDA delays verdict on AZ breast cancer drug

FDA's ODAC delivers one loss, one win for AstraZeneca

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

Data cues up AZ oral SERD filing in first-line breast cancer

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for cla...

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

camizestrant

Editor's Picks